Furthermore, equivalent ASXL truncations have been shown to be sensitive to HDAC inhibitors, targeting against BRD4 activity [80], offering hope that an improved understanding of mechanisms underlying disrupted PR-DUB regulation can lead to improved options for the treatment of cancers where these disruptions occur. This evidence concerns the gene ZUP1 and cancer.